CSF1R and neoplasm: We observed a similar result by flow cytometry, with anti-PD-L1 + anti-TIGIT treatment, but not anti-PD-L1 + anti-TIGIT + anti-CSF-1R treatment, driving a reduced expression of TOX in tumour CD8+ T cells (Fig. 6b).